Advertisement

Clinical and Translational Oncology

, Volume 18, Issue 8, pp 848–858 | Cite as

Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

  • O. Abdel-RahmanEmail author
  • H. ElHalawani
  • H. Ahmed
Brief Research Article

Abstract

Back ground

We executed a comparative systematic review and meta-analysis of the efficacy and toxicity of doublet BRAF/MEK inhibition versus single-agent BRAF inhibitor in the management of BRAF-mutant advanced melanoma.

Methods

Eligible studies included prospective studies evaluating doublet regimens versus BRAF-inhibitor monotherapy for the management of BRAF-mutant advanced melanoma.

Results

Our search strategy yielded 200 potentially relevant citations from searched databases. After preclusion of ineligible studies, four studies were included in the final analysis. Efficacy analyses demonstrate that BRAF/MEK inhibition strategy is associated with a significant improvement in ORR [OR 1.35; 95 % CI (1.16, 1.58); P = 0.0002], PFS [HR 0.56; 95 % CI (0.49, 0.64); P < 0.00001] and OS [HR 0.70; 95 % CI (0.58, 0.84); P = 0.0001]. Moreover, this combination is associated with a higher RR for diarrhea [1.30; 95 % CI (1.30, 1.49); P = 0.0002], decreased ejection fraction [4.63; 95 % CI (2.56, 8.37); P = <0.00001], acneiform dermatitis [1.61; 95 % CI (1.03, 2.53); P = 0.04] and pyrexia [1.98; 95 % CI (1.72, 2.27); P < 0.00001].

Conclusions

Our meta-analysis has demonstrated that combination of MEK/BRAF inhibitors is associated with higher ORR, PFS and OS. However, this comes at the expense of a higher risk of selected toxicities.

Keywords

Melanoma Trametinib Dabrafenib Vemurafenib 

Notes

Compliance with ethical standards

This study has not funded by any organizational body.

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    Song X, Zhao Z, Barber B, Farr AM, Ivanov B, Novich M. Overall survival in patients with metastatic melanoma. Curr Med Res Opin. 2015;31(5):987–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer. 2014;134(12):2961–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Michielin O, Höller C. Gaining momentum: new options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev. 2015.Google Scholar
  4. 4.
    Weise AM, Flaherty LE. New options for the adjuvant treatment of cutaneous melanoma? Curr Oncol Rep. 2014;16(11):1–6.CrossRefGoogle Scholar
  5. 5.
    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 2005;5(4):350–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010;399(3):313–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Cantwell-Dorris ER, O’Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10(3):385–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.CrossRefPubMedGoogle Scholar
  13. 13.
    Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014.Google Scholar
  14. 14.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88.CrossRefPubMedGoogle Scholar
  17. 17.
    Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.CrossRefPubMedGoogle Scholar
  19. 19.
    Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.CrossRefPubMedGoogle Scholar
  22. 22.
    Abdel-Rahman O, ElHalawani H, Ahmed H, Ellithy M. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2015 (ahead-of-print):1–13.Google Scholar
  23. 23.
    Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected cardiovascular toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Glob Oncol. 2015 (ahead-of-print):1–13.Google Scholar
  24. 24.
    Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Future Oncol. 2015 (ahead-of-print):1–13.Google Scholar
  25. 25.
    Gutzmer R, Hassel J, Kähler K, Loquai C, Mössner R, Ugurel S, et al. Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors. Der Hautarzt Z Dermatol Venerol Verwandte Geb. 2014;65(7):582–9.Google Scholar
  26. 26.
    Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015.Google Scholar
  27. 27.
    Yaeger R, Cercek A, O’Reilly E, Reidy E, editors. Pilot study ofvemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer. American Society of Clinical Oncology, 50th annual meeting, Chicago.Google Scholar
  28. 28.
    Planchard D, Groen H., Kim T, Rigas J, Souquet P, Baik C et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. [2015 ASCO annual meeting (29 May–2 June 2015)]. 2015;33(15_suppl, May 20 supplement):8006.Google Scholar
  29. 29.
    Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015.Google Scholar
  30. 30.
    Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma a pooled analysis of 4 clinical trials. JAMA Oncol. 2015.Google Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  1. 1.Clinical Oncology Department, Faculty of MedicineAin Shams UniversityCairoEgypt
  2. 2.Clinical Oncology DepartmentNasser InstituteCairoEgypt

Personalised recommendations